CANBRIDGE PHARM.DL-00001 (MF1) — Tangible Net Worth Ratio
CANBRIDGE PHARM.DL-00001 (MF1) has a Tangible Net Worth Ratio of 77.9% as of December 2022. This metric is calculated by deducting intangible assets (€68.13 Million) from net assets (€308.56 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See MF1 net assets for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
CANBRIDGE PHARM.DL-00001 Tangible Net Worth Ratio (2021–2022)
This chart shows how CANBRIDGE PHARM.DL-00001's Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2022. As of December 2022, the ratio stands at 77.9%, reflecting net assets of €308.56 Million with intangible assets of €68.13 Million EUR. Also explore MF1 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for CANBRIDGE PHARM.DL-00001 (2021–2022)
The table below presents the year-by-year Tangible Net Worth Ratio for CANBRIDGE PHARM.DL-00001 from 2021 to 2022, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see MF1 stock market capitalisation.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2022 | 77.9% | €308.56 Million | €68.13 Million | €702.04 Million | ▼ -14.7 pp |
| 2021 | 92.6% | €693.39 Million | €51.27 Million | €892.52 Million | — |